These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

384 related items for PubMed ID: 15629834

  • 1. Intravitreal triamcinolone-induced elevated intraocular pressure is associated with the development of posterior subcapsular cataract.
    Gillies MC, Kuzniarz M, Craig J, Ball M, Luo W, Simpson JM.
    Ophthalmology; 2005 Jan; 112(1):139-43. PubMed ID: 15629834
    [Abstract] [Full Text] [Related]

  • 2. Cataract formation and other complications of intravitreal triamcinolone for macular edema.
    Thompson JT.
    Am J Ophthalmol; 2006 Apr; 141(4):629-37. PubMed ID: 16564796
    [Abstract] [Full Text] [Related]

  • 3. Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial.
    Gillies MC, Sutter FK, Simpson JM, Larsson J, Ali H, Zhu M.
    Ophthalmology; 2006 Sep; 113(9):1533-8. PubMed ID: 16828501
    [Abstract] [Full Text] [Related]

  • 4. Intravitreal triamcinolone will cause posterior subcapsular cataract in most eyes with diabetic maculopathy within 2 years.
    Islam MS, Vernon SA, Negi A.
    Eye (Lond); 2007 Mar; 21(3):321-3. PubMed ID: 16543927
    [Abstract] [Full Text] [Related]

  • 5. Cataract progression after intravitreal triamcinolone injection.
    Cekiç O, Chang S, Tseng JJ, Akar Y, Barile GR, Schiff WM.
    Am J Ophthalmol; 2005 Jun; 139(6):993-8. PubMed ID: 15953428
    [Abstract] [Full Text] [Related]

  • 6. Secondary elevated IOP and cataracts after high-dose intravitreal triamcinolone and photodynamic therapy to treat choroidal neovascularization.
    Ruiz-Moreno JM, Montero JA, Amat P, Lugo FL.
    J Glaucoma; 2009 Jan; 18(1):69-72. PubMed ID: 19142138
    [Abstract] [Full Text] [Related]

  • 7. Objective evaluation of cataract progression associated with a high dose intravitreal triamcinolone injection.
    Chu YK, Chung EJ, Kwon OW, Lee JH, Koh HJ.
    Eye (Lond); 2008 Jul; 22(7):895-9. PubMed ID: 17435692
    [Abstract] [Full Text] [Related]

  • 8. Intravitreal triamcinolone acetonide for treatment of intraocular oedematous and neovascular diseases.
    Jonas JB.
    Acta Ophthalmol Scand; 2005 Dec; 83(6):645-63. PubMed ID: 16396641
    [Abstract] [Full Text] [Related]

  • 9. Prospective, randomized clinical trial of intravitreal triamcinolone treatment of neovascular age-related macular degeneration: one-year results.
    Lee J, Freeman WR, Azen SP, Chung EJ, Koh HJ.
    Retina; 2007 Dec; 27(9):1205-13. PubMed ID: 18046226
    [Abstract] [Full Text] [Related]

  • 10. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection.
    Jonas JB, Degenring RF, Kreissig I, Akkoyun I, Kamppeter BA.
    Ophthalmology; 2005 Apr; 112(4):593-8. PubMed ID: 15808249
    [Abstract] [Full Text] [Related]

  • 11. Comparison of intravitreal versus posterior sub-Tenon's capsule injection of triamcinolone acetonide for diffuse diabetic macular edema.
    Cardillo JA, Melo LA, Costa RA, Skaf M, Belfort R, Souza-Filho AA, Farah ME, Kuppermann BD.
    Ophthalmology; 2005 Sep; 112(9):1557-63. PubMed ID: 16019075
    [Abstract] [Full Text] [Related]

  • 12. Adverse events after intravitreal triamcinolone in patients with and without uveitis.
    Galor A, Margolis R, Brasil OM, Perez VL, Kaiser PK, Sears JE, Lowder CY, Smith SD.
    Ophthalmology; 2007 Oct; 114(10):1912-8. PubMed ID: 17908594
    [Abstract] [Full Text] [Related]

  • 13. Secondary ocular hypertension after intravitreal injection of 4 mg of triamcinolone acetonide: incidence and risk factors.
    Vasconcelos-Santos DV, Nehemy PG, Schachat AP, Nehemy MB.
    Retina; 2008 Apr; 28(4):573-80. PubMed ID: 18398360
    [Abstract] [Full Text] [Related]

  • 14. Outcome of intravitreal triamcinolone in uveitis.
    Kok H, Lau C, Maycock N, McCluskey P, Lightman S.
    Ophthalmology; 2005 Nov; 112(11):1916.e1-7. PubMed ID: 16171868
    [Abstract] [Full Text] [Related]

  • 15. Long-term follow-up results of a pilot trial of a fluocinolone acetonide implant to treat posterior uveitis.
    Jaffe GJ, McCallum RM, Branchaud B, Skalak C, Butuner Z, Ashton P.
    Ophthalmology; 2005 Jul; 112(7):1192-8. PubMed ID: 15921758
    [Abstract] [Full Text] [Related]

  • 16. Intravitreal triamcinolone acetonide injection at the end of vitrectomy for diabetic vitreous hemorrhage: a randomized, clinical trial.
    Faghihi H, Taheri A, Farahvash MS, Esfahani MR, Rajabi MT.
    Retina; 2008 Oct; 28(9):1241-6. PubMed ID: 18626423
    [Abstract] [Full Text] [Related]

  • 17. Cataract surgery after intravitreal injection of triamcinolone acetonide.
    Jonas JB, Kreissig I, Degenring RF.
    Eye (Lond); 2004 Apr; 18(4):361-4. PubMed ID: 15069430
    [Abstract] [Full Text] [Related]

  • 18. Safety and efficacy of intraoperative intravitreal injection of triamcinolone acetonide injection after phacoemulsification in cases of uveitic cataract.
    Dada T, Dhawan M, Garg S, Nair S, Mandal S.
    J Cataract Refract Surg; 2007 Sep; 33(9):1613-8. PubMed ID: 17720079
    [Abstract] [Full Text] [Related]

  • 19. The effect of intravitreal triamcinolone on intraocular pressure.
    Kramar M, Vu L, Whitson JT, He YG.
    Curr Med Res Opin; 2007 Jun; 23(6):1253-8. PubMed ID: 17559723
    [Abstract] [Full Text] [Related]

  • 20. A prospective study of early intraocular pressure changes after a single intravitreal triamcinolone injection.
    Im L, Allingham RR, Singh I, Stinnett S, Fekrat S.
    J Glaucoma; 2008 Mar; 17(2):128-32. PubMed ID: 18344759
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.